Background Following a 30-year development process, RTS, S/AS01E (GSK, Belgium) is
the first malaria vaccine to reach Phase IV assessments. The World Health Organization …

A workshop on implementation strategies for the introduction of the RTS, S/AS01 (RTS, S)
malaria vaccine in countries with areas of highly seasonal transmission, was held as a …

The malaria vaccine candidate, RTS, S/AS01E, showed promising protective efficacy in a
trial of Kenyan and Tanzanian children aged 5 to 17 months. Here we report on the …

Background The development of a malaria vaccine remains a public health priority for sub‐
Saharan Africa. RTS, S/AS02A candidate malaria vaccine has been shown to be safe and …

Summary Background The RTS, S/AS01 E malaria vaccine (RTS, S) was introduced by
national immunisation programmes in Ghana, Kenya, and Malawi in 2019 in large-scale …

Abstract Background GlaxoSmithKline Biologicals and the PATH Malaria Vaccine Initiative
are working in partnership to develop a malaria vaccine to protect infants and children living …

Background The Malaria Vaccine Implementation Program, coordinated by the World Health
Organization, intended to initiate the roll-out of the RTS, S/AS01 malaria vaccine in 3 sub …

Introduction In malaria‐stricken regions, malaria continues to be one of the primary causes
of mortality for children. The number of malaria‐related fatalities has drastically decreased …

Abstract Background In 2019, the RTS, S/AS01E malaria vaccine was introduced on a pilot
basis in six regions of Ghana by the Ministry of Health/Ghana Health Service as part of the …

In October 2021, the WHO recommended the world's first malaria vaccine—RTS, S/AS01—
to prevent malaria in children living in areas with moderate-to-high transmission in sub …